Archives: Agenda
CASE STUDY Reducing Time to Rare Disease Diagnosis Through AI and Data-Driven Care Pathways
- Identifying where AI is already improving diagnosis
- Integrating AI into existing clinical workflows
- Overcoming implementation and governance challenges
- Measuring impact on referral pathways and patient outcomes
FOCUS SESSION + EXPERT COMMENTARY Keeping Patients on Treatment — Overcoming the Hidden Barriers to Successful Oncology Trials
- Understanding why patients discontinue treatment or follow-up
- Educating patients on the value of remaining in clinical trials
- Balancing long-term study requirements with patients’ treatment opportunities
- Designing studies that support both retention and patient choice
Morning refreshments and networking break
Morning refreshments and networking break
The Future of Rare Disease Clinical Development — Delivering Innovation for Small Patient Populations
- The biggest opportunities changing rare disease development
- How sponsors can accelerate development without increasing operational risk
- Emerging regulatory and scientific priorities
- Where collaboration will matter most over the next five years
PANEL DISCUSSION Choosing Where to Run Oncology Trials in 2027 — Balancing Cost, Speed and Patient Access
- Balancing scientific objectives alongside cost, timelines and recruitment potential
- Understanding how standards of care and comparator availability influence country selection
- Exploring opportunities in emerging regions while maintaining study quality
- Selecting countries that improve both operational delivery and scientific validity
Session reserved for event sponsor
Session reserved for event sponsor
OPENING KEYNOTE Preparing for the MHRA’s Proposed Rare Disease Therapies Regulatory Framework – What Sponsors Need to Know
- The proposed framework
- Impact on rare disease developers
- Practical implications
- Questions from sponsors
Reserved for NIHR